11.03.26 -- How Manufacturing Changes Can Create Risk For MSCs

Discover why purpose-built technologies and industry collaboration are essential for scaling cell and gene therapies while improving consistency and protecting critical cellular biology.

Learn how a scalable, non-viral electroporation platform successfully delivers complex genetic payloads while ensuring high cellular efficiency and viability from discovery to production.

Hear a researcher's firsthand account of moving from lab to production scale, revealing what bioreactor scaling and high-density perfusion actually demand in everyday practice.

Explore the latest in lentiviral vector release testing, which covers biosafety, regulatory insights, and QC strategies to ensure patient safety and accelerate your path to clinic.

Successful bioprocess technology transfer relies on effective knowledge sharing, supply chain readiness, analytical method transfer, and quality oversight to reduce risk and support scale-up.

Gain practical insights into the manufacturing realities shaping in vivo CAR-T development and learn how leading teams are addressing the challenges of scaling both LNP and viral vector platforms."

In this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. address the transition from early development into larger-scale manufacturing and why process changes can introduce biological and comparability risks.